Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CKSF1B1.
Type:
Application
Filed:
April 7, 2010
Publication date:
September 16, 2010
Applicant:
DHARMACON, INC.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
Type:
Application
Filed:
April 12, 2010
Publication date:
September 16, 2010
Applicant:
DHARMACON, INC.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
Type:
Grant
Filed:
October 29, 2007
Date of Patent:
September 14, 2010
Assignee:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.
Type:
Grant
Filed:
October 17, 2007
Date of Patent:
September 14, 2010
Assignee:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
Abstract: The present invention provides compounds of the formula (I): C-Q-O—Si(R1)(R2)—N wherein C is a chromophore; Q is selected from the group consisting of optionally substituted aliphatic, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R1 and R2 are independently selected from the group consisting of optionally substituted C1-8 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-8 alkyloxy, cycloalkyloxy, heterocycloalkyloxy, alkylsilyloxy and arylsilyloxy; and N is a glycosylamine or abasic moiety.
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
Type:
Grant
Filed:
September 18, 2009
Date of Patent:
August 24, 2010
Assignee:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Methods and compositions for performing RNA interference comprising a wide variety of stabilized siRNAs suitable for use in serum-containing media and for in vivo applications, such as therapeutic applications, are provided. These siRNAs permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of one or more modifications including orthoesters, terminal conjugates, modified linkages and 2? modified nucleotides. Uniquely modified siRNAs have been developed that reduces off-target effects incurred in gene-silencing. The modifications include phosphorylation of the first 5? terminal antisense nucleotide; 2? carbon modifications of the first and second or first, second, and third 5? terminal antisense nucleotides; and optionally 2? carbon modifications of the first and second or first, second, and third 5? terminal sense nucleotide. Control and exaequo molecules are also provided.
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2.
Type:
Application
Filed:
March 1, 2010
Publication date:
July 29, 2010
Applicant:
DHARMACON, INC.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: The present invention provides compositions and methods for inhibiting gene silencing by the RNAi pathway. The RNAi inhibitors of the invention have a reverse complement (RC) region to the target molecule of interest (e.g., miRNA) in association with at least one flanking region coupled to either at the 3? or 5? end of the RC region. The flanking regions can be single-stranded or can have one or more regions of double stranded nucleic acid with or without a hairpin loop. The RNAi inhibitors described herein can inhibit endogenous targets, including but not limited to microRNAs, or piRNAs, or can be used to inhibit the effects of exogenously introduced molecules, such as synthetic siRNAs, siRNAs expressed from vector constructs (e.g., viral expression systems), or siRNAs generated by enzymatic methods. Inhibition is specific, potent, prolonged, and can be performed on a single target or multiple targets simultaneously.
Type:
Application
Filed:
February 16, 2007
Publication date:
July 22, 2010
Applicant:
Dharmacon, Inc.
Inventors:
Annaleen Vermeulen, Barbara Robertson, Scott Baskerville, Christina Yamada, Devin Leake, Yuriy Fedorov, Jon Karpilow, Anastasia Khvorova
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.
Type:
Grant
Filed:
July 28, 2009
Date of Patent:
June 29, 2010
Assignee:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CDK11.
Type:
Grant
Filed:
May 29, 2007
Date of Patent:
June 29, 2010
Assignee:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Type:
Grant
Filed:
July 6, 2009
Date of Patent:
June 29, 2010
Assignee:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CKSF1B1.
Type:
Grant
Filed:
May 28, 2009
Date of Patent:
June 22, 2010
Assignee:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Type:
Application
Filed:
January 15, 2010
Publication date:
June 17, 2010
Applicant:
DHARMACON INC.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
Type:
Grant
Filed:
August 4, 2009
Date of Patent:
June 15, 2010
Assignee:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Type:
Application
Filed:
January 26, 2010
Publication date:
June 10, 2010
Applicant:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to STK12.
Type:
Application
Filed:
January 21, 2010
Publication date:
June 10, 2010
Applicant:
DHARMACON, INC.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE.
Type:
Application
Filed:
December 11, 2009
Publication date:
May 6, 2010
Applicant:
DHARMACON, INC.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88.
Type:
Application
Filed:
December 8, 2009
Publication date:
May 6, 2010
Applicant:
DHARMACON, INC.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.
Type:
Application
Filed:
December 23, 2009
Publication date:
May 6, 2010
Applicant:
DHARMACON, INC.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe